Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis

INTRODUCTION: Randomized studies have shown that bortezomib (BTZ) can be given weekly via intravenous (IV) route or twice weekly via subcutaneous (SC) route with lower neuropathy risk and no loss of anti-myeloma efficacy compared to original standard IV twice weekly schedule. Weekly SC should theref...

Full description

Saved in:
Bibliographic Details
Published in:PLoS One
Main Authors: Sidana, Surbhi, Narkhede, Mayur, Elson, Paul, Hastings, Debbie, Faiman, Beth, Valent, Jason, Samaras, Christy, Hamilton, Kimberly, Liu, Hien K., Smith, Mitchell R., Reu, Frederic J.
Format: Artigo
Language:Inglês
Published: Public Library of Science 2017
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5344345/
https://ncbi.nlm.nih.gov/pubmed/28278302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0172996
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items